Why the study?
Coronary endothelial cell injury during myocardial ischemia-reperfusion injury in diabetic mice with ALDH2 deficiency had not been studied.
Does Alda-1 pretreatment reduce myocardial infarct size and cardiac dysfunction in diabetic ALDH2*2 mutant mice subjected to ischemia-reperfusion injury?
Does Alda-1 pretreatment reduce myocardial infarct size and cardiac dysfunction in diabetic ALDH2*2 mutant mice subjected to ischemia-reperfusion injury?
ALDH2 activation with Alda-1 reverses the exacerbated 4HNE-mediated coronary endothelial cell injury and cardiac dysfunction seen in diabetic ALDH2*2 mutant mice after ischemia-reperfusion injury.
Answers are grounded in this paper and cite their sources.
ALDH2*2 may heighten CEC vulnerability in diabetic myocardial IRI; leaves open clinical translation or targeted therapies.
Background Aldehyde dehydrogenase-2 (ALDH2), a mitochondrial enzyme, detoxifies reactive aldehydes such as 4-hydroxy-2-nonenal (4HNE). A highly prevalent E487K mutation in ALDH2 (ALDH2*2) in East Asian people with intrinsic low ALDH2 activity is implicated in diabetic complications. 4HNE-induced cardiomyocyte dysfunction was studied in diabetic cardiac damage; however, coronary endothelial cell (CEC) injury in myocardial ischemia-reperfusion injury (IRI) in diabetic mice has not been studied. Therefore, we hypothesize that the lack of ALDH2 activity exacerbates 4HNE-induced CEC dysfunction which leads to cardiac damage in ALDH2*2 mutant diabetic mice subjected to myocardial IRI. Methods and Results Three weeks after diabetes mellitus (DM) induction, hearts were subjected to IRI either in vivo via left anterior descending artery occlusion and release or ex vivo IRI by using the Langendorff system. The cardiac performance was assessed by conscious echocardiography in mice or by inserting a balloon catheter in the left ventricle in the ex vivo model. Just 3 weeks of DM led to an increase in cardiac 4HNE protein adducts and, cardiac dysfunction, and a decrease in the number of CECs along with reduced myocardial ALDH2 activity in ALDH2*2 mutant diabetic mice compared with their wild-type counterparts. Systemic pretreatment with Alda-1 (10 mg/kg per day), an activator of both ALDH2 and ALDH2*2, led to a reduction in myocardial infarct size and dysfunction, and coronary perfusion pressure upon cardiac IRI by increasing CEC population and coronary arteriole opening. Conclusions Low ALDH2 activity exacerbates 4HNE-mediated CEC injury and thereby cardiac dysfunction in diabetic mouse hearts subjected to IRI, which can be reversed by ALDH2 activation.
No takes yet. Share an insight, caveat, or question.
Pan et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: